Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
Immune Response BioPharma, Inc. TM     Copyright  © 2010-2018 

Investor Relations: 
undefined
Immune Response BioPharma, Inc. is a Delaware Corporation & Shareholder Friendly Focused on Maximizing Value.
The Company has a strong product pipeline to develop with multiple compounds to bring to market to save lives.


NeuroVax: MS Vaccine NeuroVax Video  NeuroVax TM is our Flagship Vaccine for Multiple Sclerosis has been Granted both Pediatric Orphan Designation & FDA Fast Track Designation for SPMS

  undefined                                                                                
REMUNE: HIV-1 Immunogen First in Class & Best in Class HIV/AIDS Vaccine has been Granted Pediatric Orphan Designation
 

 
Patent Coverage through 2027 with The King Patent U.S. Patent 8,053,197 Granted Ownership Issued to Immune Response BioPharma, Inc. for Auto-Immune Diseases Proprietary FOXP3+ Expression Technology.
 
Dividends: The Company plans to pay regular dividends Annually 
 
Partnering: By Partnering out manufacturing and drug development the company intends to become a royalty generating income producing company.
 
All pipeline drugs are Eligible for 5 years exclusivity under the Hatch Waxman Act for new chemical entities & the FDA has Granted Pediatric Orphan Designation for REMUNE & NeuroVax for 7 years exclusivity. The King Patent U.S. 8,053,197 Extends IP Coverage thru 2027 for Auto-Immune Disease Treatement & Vaccination.
 
Immune Response BioPharma, Inc. TM  
All Rights Reserved









Copyright © 2010-2018   www.immuneresponse.net